Dr Reddy’s Laboratories saw a 2% rise in consolidated net profit to Rs 1,413 crore in Q3 FY24, driven by strong market performance. Revenue grew to Rs 8,359 crore, with notable growth in the US, Indian, European, and emerging markets. Key factors included the newly acquired NRT business, product launches, and enhanced operational efficiencies.